- Home
- GNTA vs LTRN Comparison
GNTA vs LTRN Comparison
Compare GNTA & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | LTRN |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 27.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNTA | LTRN |
|---|---|---|
| Price | $0.69 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.2K | ★ 233.7K |
| Earning Date | 03-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.08 |
| 52 Week High | $10.00 | $4.70 |
Technical Indicators
Market Signals| Indicator | GNTA | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 19.79 |
| Support Level | $0.58 | N/A |
| Resistance Level | $0.74 | $1.96 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 29.10 | 7.35 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.